PDC*line Pharma

Et si un vaccin contre le cancer du poumon venait de Wallonie ? 🔬🫁 La biotech wallonne PDC*line Pharma, membre de la #Sambrinvestgalaxy, a récemment annoncé des résultats cliniques encourageants pour son vaccin contre le cancer du poumon. Ces résultats confirment son efficacité ainsi que son profil de sécurité et laissent entrevoir de nouvelles options thérapeutiques plus efficaces et accessibles pour les patients. 👨🏻🔬 Pour en savoir plus 👉🏻 https://lnkd.in/e86fGxKc Eric Halioua, Frederique Cantero, Elisabeth de Halleux

🎯 À lire absolument ! Découvrez l'article publié dans L'Echo intitulé "Des résultats cliniques positifs pour le vaccin anticancer de PDC*line Pharma", qui met en lumière les avancées prometteuses de notre technologie et les éléments différenciateurs de notre vaccin contre le cancer. 📢 Une interview exclusive de notre CEO, Eric Halioua, y est également présentée, où il partage la vision et l’impact potentiel de notre innovation sur les traitements contre le cancer. 👉 Lien vers l'article : https://lnkd.in/e86fGxKc

a landmark achievment for PDC line Pharma !

We are thrilled to share the primary clinical results from our Phase I/II trial of the PDC*lung01 cancer vaccine, presented at ESMO-IO 2024! 💡 Key Highlights: - PDC*lung01, combined with pembrolizumab, shows potential for meaningful clinical benefit compared to pembrolizumab alone in stage IV Non-Small Cell Lung Cancer patients with PD-L1 ≥ 50%. - The combination therapy demonstrated a confirmed objective response rate of 55% across 42 evaluable patients, meeting the trial’s predefined objectives. - Median progression-free survival: 8.9 months representing a 36% relative increase compared to Keynote-042. - Immune response: A higher response is significantly linked to improved clinical outcomes (e.g., progression-free survival). - Safety profile: Mild and manageable. These results reinforce the promise of PDC*lung01 as a novel and effective immunotherapy approach. We remain committed to advancing breakthroughs in cancer care and are excited to continue our mission of making a difference for patients. 👉 Stay tuned for more updates as we progress! #CancerResearch #Immunotherapy #ESMOIO2024 #NSCLC #PDCLung01 #InnovationInHealth

In Wallonia, innovation in the fight against cancer is at the top of the world, thanks to the presence of leading companies in ATMPs, nuclear medicine, immunotherapy, precision medicine, and proton therapy, supported by exceptional academics and clinicians. Great news for patients—and a prime opportunity for investors to align impact with profit. 👉 Read this interesting article mentioning PDC*line Pharma https://lnkd.in/ev6nhjUg

"L'oncologie, l'Eldorado wallon pour les investisseurs ?" 👩🔬✨ Le secteur s'affirme comme la prochaine révolution des sciences de la vie. Un terreau également fertile pour les investisseurs, qui peuvent combiner impact sociétal et rentabilité financière. Envie d'en savoir plus ? Retrouvez ci-dessous l'intégralité de la carte blanche publiée par Amel Tounsi (Bridge to Health (B2H)) et Eric Brandt (Noshaq) dans L'Echo.

🇧🇪 Belgium’s innovative biopharmaceutical sector invests 7x more in R&D compared to the EU27 average. With a daily investment of €15.5 million, Belgium has solidified its position as a European leader in pharmaceutical research and development. “It is the result of years of consistent work. Over the period 2018–2022, the per-capita Belgian R&D expenditure in the biopharmaceutical sector increased by more than 56%. This is almost 2.5 times the growth percentage for R&D expenditure per capita in the EU overall. No other country with significant R&D expenditure per capita established such a major growth,” stated Pharma.be. 👉 https://lnkd.in/e2qwkXkX 👉 Find more details in pharma.be’s latest report: https://lnkd.in/eHHFXgaT

We've had the great opportunity to speak to Eric Halioua, CEO of PDC*line Pharma, on the company’s journey from its inception to its current breakthroughs in cancer immunotherapies. Eric shared insights on the drive behind PDC*line Pharma's unique platform, the resilience required to push forward in biotech, and the impact of global partnerships. Stay tuned for more on how PDC*line Pharma is advancing clinical trials and what we can expect to hear from them at Cell and Gene Therapy International Europe, this December! Read more below: #cellandgenetherapy #biotech #bioprocessing

PDC*line Pharma is thrilled to announce that the primary clinical analysis results from our Phase I/II trial (PDC-LUNG-101) will be presented as a mini oral presentation at the ESMO - European Society for Medical Oncology -Immuno-Oncology Congress 2024! This study evaluates our innovative therapeutic cancer vaccine, PDC*lung01, in combination with anti-PD-1 for untreated stage IV Non-Small Cell Lung Cancer (NSCLC) patients. The congress will be held in Geneva, Switzerland, from December 11-13, 2024. We’re honored that Prof. Johan F. Vansteenkiste (Leuven, Belgium) will present these results. Mini Oral Presentation Details: Title: Phase I/II trial evaluating the therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in untreated stage IV NSCLC patients Abstract Number: 119MO Session Title: Mini Oral Session 2 Date / Time: December 12, 2024, at 14:50 pm CEST Note: ESMO-IO will publish all late-breaking abstracts online on December 10, 2024, at 00:05 CET via the ESMO website. We look forward to contributing to the advancement of cancer immunotherapy at this esteemed event! https://lnkd.in/eWJrdxdP

✨ We are thrilled to announce that we have been selected for an oral presentation at the “Educational Days” of the Francophone Society of Histocompatibility and Immunogenetics (SFHI), held in Strasbourg from October 9 to 11, 2024! ✨ 📢 The presentation, delivered yesterday by Séverine PLANEL, was titled: "Study of the humoral response of cancer patients (DSA) to a cellular vaccine based on an allogenic plasmacytoid dendritic cell line, in combination or not with anti-PD1 treatment." Following our presentations at the annual conferences of AACR, CIMT, EFI, and the 50th Annual Meeting of the Korean Cancer Association (KCA 2024), this is our fifth oral presentation of clinical results at an international and prestigious medical/scientific conference this year! 🔗 Learn more about the event: https://lnkd.in/gz5SQndR #ScientificResearch #Oncology #Immunotherapy #InternationalConference #Innovation #SFHI2024